Q4 Earnings Estimate for Annovis Bio Issued By HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS) – HC Wainwright dropped their Q4 2024 earnings estimates for shares of Annovis Bio in a report released on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.38) for the quarter, down from their prior estimate of ($0.30). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Annovis Bio’s current full-year earnings is ($1.99) per share. HC Wainwright also issued estimates for Annovis Bio’s Q1 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.76) EPS and FY2025 earnings at ($2.32) EPS.

Annovis Bio (NYSE:ANVS) last issued its earnings results on Friday, November 8th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.33).

Other research analysts also recently issued reports about the stock. Maxim Group raised shares of Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Friday, October 25th. EF Hutton Acquisition Co. I raised Annovis Bio to a “strong-buy” rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $32.17.

Annovis Bio Price Performance

NYSE:ANVS opened at $7.41 on Thursday. The stock’s 50-day moving average is $8.47 and its two-hundred day moving average is $8.27. The stock has a market cap of $102.26 million, a PE ratio of -1.66 and a beta of 1.70. Annovis Bio has a fifty-two week low of $4.53 and a fifty-two week high of $22.49.

Institutional Investors Weigh In On Annovis Bio

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Annovis Bio by 6.1% during the 1st quarter. Vanguard Group Inc. now owns 357,942 shares of the company’s stock worth $4,260,000 after purchasing an additional 20,588 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Annovis Bio in the third quarter worth $371,000. XTX Topco Ltd bought a new position in Annovis Bio during the second quarter worth $115,000. Greenwich Wealth Management LLC raised its stake in Annovis Bio by 9.3% during the 3rd quarter. Greenwich Wealth Management LLC now owns 16,475 shares of the company’s stock valued at $133,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Cetera Advisors LLC acquired a new position in Annovis Bio during the 1st quarter valued at $122,000. Institutional investors own 15.83% of the company’s stock.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.